Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

Abstract Background Although several previous studies tested SGLT2 inhibitors in the setting of an acute, non-cardiovascular illness, detailed information on their efficacy and safety among participants with and without type 2 diabetes (T2D) from double-blind randomized trials is lacking. In this se...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammad Abdel Jawad, Remo H. M. Furtado, Russell Esterline, Jan Oscarsson, Samvel B. Gasparyan, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Anna Maria Langkilde, Philip Ambery, Shachi Patel, Kensey Gosch, Sheryl L. Windsor, Ronaldo V. P. Soares, Diogo D. F. Moia, Matthew Aboudara, Ali Javaheri, J. F. Kerr Saraiva, Lilia Nigro Maia, Otavio Berwanger, Andrew J. Sauer, Mikhail N. Kosiborod
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Cardiovascular Diabetology
Subjects:
Acute illness
Dapagliflozin
Sodiu
m-glucose co-transporter-2 inhibitors
Safety
Type 2 diabetes
Online Access:https://doi.org/10.1186/s12933-025-02875-6
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items